Ekso Bionics (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, January 9th.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, ValuEngine raised shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a report on Friday, November 17th.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $2.40 million. equities analysts anticipate that Ekso Bionics will post -0.81 EPS for the current fiscal year.
In related news, insider Russ Angold sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 3.32% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. National Planning Corp raised its position in shares of Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after buying an additional 286,492 shares during the last quarter. Carl Domino Inc raised its position in shares of Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after buying an additional 102,734 shares during the last quarter. Intellectus Partners LLC raised its position in shares of Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the last quarter. Institutional investors own 6.22% of the company’s stock.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.